- InterView
- From domestic sales to the global brand general
- by Dec 22, 2022 05:53am
- Considering healthcare systems around the world such as in Russia, the Middle East, Southeast Asia, and South America, the company will set up a strategy to launch a new anti-cancer drug. It is the main job of Kim Soo-yeon (48), executive director of the International Lung Cancer Brand, at AstraZeneca. Managing director Kim's role has also grown
- Company
- New HCV drug Epclusa lands in hospitals with reimb
- by Eo, Yun-Ho Dec 22, 2022 05:52am
- The Hepatitis C treatment ‘Epclusa’ is rapidly landing in hospitals for prescriptions after being granted reimbursement in Korea. According to industry sources, Gilead Science Korea’s oral chronic hepatitis C treatment Epclusa (sofosbuvir/velpatasvir) has passed the Drug Committees (DCs) of the Big-5s including the Seoul National Unive
- Company
- Dong-A ST introduces candidate substance technology
- by Kim, Jin-Gu Dec 22, 2022 05:52am
- Global joint development of immuno-cancer drugs under the mechanism of double fusion antibodies and acquisition of exclusive sales rights Dong-A ST announced on the 21st that it has signed a license agreement with Kanaph Therapeutics to license candidate substances for immuno-cancer drugs under the dual fusion antibody mechanism. Dong-AST
- Product
- Get rid of Imotun & Godex which waste taxpayers' money
- by Dec 22, 2022 05:52am
- Pharmaceutical Society for a Healthy Society (CEO Shin Hyung-geun) has called for the expulsion of Imotun and Godex. In a statement on the 21st, the Pharmaceutical Association for Health Society argued that maintaining health insurance benefits for six-component compounds (Godex) including avocado-soya unexamined (Imotun) and adenine hydrochl
- Policy
- New reimbursement standards set for Kymriah·Zolgensma
- by Kim, Jung-Ju Dec 22, 2022 05:52am
- New reimbursement standards have been set for high-priced pharmaceuticals like Kymriah and Zolgensma, the so-called ‘one-shot treatments.’ Also, reimbursement standards will be newly established for the second CGRP-targeted therapy for migraine, Ajovy (fremanezumab), and the new tuberculosis drug Dovprela 200mg (pretomanid) that had bee
- Company
- PO SMA tx Indication of Evrysdi expands
- by Eo, Yun-Ho Dec 21, 2022 06:05am
- Evrysdi, a PO SMA treatment, can be used for infants under 2 months in Korea. According to related industries, Evrysdi recently obtained approval from the Ministry of Food and Drug Safety to expand the indication. Accordingly, Evrysdi can be administered to newborns before symptoms appear in Korea. The expansion of neonatal indications was ba
- Policy
- Lucentis biosimilar enters KRW 35B market in Korea
- by Lee, Tak-Sun Dec 21, 2022 06:05am
- Competition in the macular degeneration treatments market is expected to intensify with the imminent entry of the first biosimilar of ‘Lucentis’ in the Korean market. Sales of Lucentis alone had been nearly KRW 35 billion in Korea last year. Lucentis biosimilars from Chong Kun Dang and Samsung Bioepis were preannounced to be listed fo
- Policy
- Shingrix will be released as a national lot on the 16th
- by Lee, Tak-Sun Dec 21, 2022 06:05am
- Shingrix (GSK), a shingles virus vaccine, received a national lot release on the 16th and began full-scale vaccination. It was also stocked in general hospitals, and vaccinations began this week. On the 16th, the Ministry of Food and Drug Safety released four production numbers (six in total, 0.5ml in packaging) with an expiration date of Oct
- Opinion
- [Reporter’s View] Preserve the industry's willpower
- by Dec 21, 2022 06:05am
- Even before the world was able to recover from the COVID-19 pandemic, a global economic recession has arrived to further the damage. With the rise in the price of raw materials, the price of every single consumable including food such as flour, sugar, and cooking oil, as well as fuel, utility bills, etc. have risen. Every day, you can see a
- Company
- Organon sold 3 types of infertility & contraceptives
- by Dec 21, 2022 06:05am
- Organon announced on the 19th that it will conduct direct sales and marketing of infertility and contraceptive products. According to Organon, the company will directly sell and market the infertility treatments Puregon and Organutran, and the implantable contraceptive Impranon in the body from next year. The company explained that it is a s
